Literature DB >> 15352916

Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin.

Q Gu1, H H-X Xia, W H Wang, J D Wang, W M Wong, A O O Chan, M F Yuen, S K Lam, H K-L Cheung, X G Liu, B C-Y Wong.   

Abstract

BACKGROUND: We previously reported that aspirin inhibited Helicobacter pylori growth and suppressed the mutagenic effect of metronidazole. AIM: To determine the effects of a cyclo-oxygenase (COX)-2-specific inhibitor, SC-236, and a non-selective COX inhibitor, indometacin, on the growth, urease activity and antimicrobial susceptibility of H. pylori.
METHODS: Three H. pylori reference strains, and 18 clinical isolates were treated with SC-236 or indometacin for 24 and 48 h. Growth, urease activity and susceptibility to clarithromycin and metronidazole of the bacteria were assessed by viable colony counting, spectrophotometry and E-test respectively.
RESULTS: SC-236 and indometacin inhibited H. pylori growth in a dose-dependent manner with the lowest inhibitory concentrations of 0.03 and 0.1 mm, and the lethal concentrations of 0.09 and 0.3 mm, respectively. The numbers of CFU/mL in Brucella broth containing 0.09 mm SC-236 were 2 log lower at 24 h, and even 3 log lower at 48 h than that at 0 h (P = 0.035, compared with the vehicle control). Treatment of 0.3 mm indometacin reduced the number of CFU/mL by 1 log at 24 h compared with that at 0 h (P = 0.037 compared with the vehicle control). Helicobacter pylori urease activity began to decrease with 0.06 mm SC-236 at 24 h (P = 0.016), and 0.3 mm indometacin at 48 h (P = 0.025). MICs of metronidazole and clarithromycin against H. pylori were decreased significantly in the presence of 0.03 mm SC-236 or 0.1 mm indometacin (all P < 0.001).
CONCLUSION: Both SC-236 and indometacin suppressed the growth and urease activity of H. pylori in a dose-dependent manner, and increased its susceptibility to the antibiotics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352916     DOI: 10.1111/j.1365-2036.2004.02168.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

Review 1.  Antimicrobial Effects of Antipyretics.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  Celecoxib inhibits Helicobacter pylori colonization-related factors.

Authors:  Jing Wang; Wei-Hong Wang; Jiang Li; Fang-Xun Liu
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

3.  Nimesulide inhibits pathogenic fungi: PGE2-dependent mechanisms.

Authors:  Rafaelle Fonseca de Matos; Lúcia Carla Vasconcelos Mendonça; Kaira Geiliane da Silva Souza; Adriana Aparecida Durães Fonseca; Elaine Mirla Souza Costa; Marcus Vinicius Dias de Lima; José Maria Dos Santos Vieira; Mioni Thielli Figueiredo Magalhães de Brito; Marta Chagas Monteiro
Journal:  Folia Microbiol (Praha)       Date:  2016-11-19       Impact factor: 2.099

Review 4.  Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.

Authors:  Elham Patrad; Solmaz Khalighfard; Taghi Amiriani; Vahid Khori; Ali Mohammad Alizadeh
Journal:  Cell Oncol (Dordr)       Date:  2022-09-23       Impact factor: 7.051

5.  Aspirin increases susceptibility of Helicobacter pylori to metronidazole by augmenting endocellular concentrations of antimicrobials.

Authors:  Xiao-Ping Zhang; Wei-Hong Wang; Yu Tian; Wen Gao; Jiang Li
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

6.  Efficacy of serology driven "test and treat strategy" for eradication of H. pylori in patients with rheumatic disease in the Netherlands.

Authors:  H T J I de Leest; K S S Steen; W F Lems; M A F J van de Laar; A M Huisman; S W Kadir; H H M L Houben; P J Kostense; E J Kuipers; B A C Dijkmans; Y J Debets-Ossenkopp
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-04       Impact factor: 3.267

7.  The bactericidal activity of carbon monoxide-releasing molecules against Helicobacter pylori.

Authors:  Ana F Tavares; Margarida R Parente; Marta C Justino; Mónica Oleastro; Lígia S Nobre; Lígia M Saraiva
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

8.  Assessment of Helicobacter pylori eradication in patients on NSAID treatment.

Authors:  Harald E Vonkeman; Htji Deleest; Mafj van Delaar; J Vanbaarlen; Kss Steen; Wf Lems; Jwj Bijlsma; Ej Kuipers; Hhml Houben; M Janssen; Bac Dijkmans
Journal:  BMC Gastroenterol       Date:  2012-09-24       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.